Abstract
Background
In Japan, the most commonly used hemofilters for patients with acute kidney injury (AKI) treated with continuous renal replacement therapy (CRRT) are made of polysulfone membranes. The aim of this study was to compare the efficacy of two commercially available polysulfone membranes for the removal of solutes.
Methods
This single-institution, prospective cross-over study was conducted between December 2010 and January 2012. Two polysulfone membranes, Hemofeel SHG (Toray) and Excelflo AEF (Asahi Kasei Medical), were compared in eight intensive care unit patients (median age, 80 years; seven men) who had severe sepsis that required CRRT and who required vasopressor treatment to maintain their mean blood pressure above 65 mmHg. The primary outcome measure was the efficacy of solute removal, evaluated for high-mobility group protein 1 (HMGB-1) and myoglobin.
Results
The main cause of sepsis was abdominal infection (50%); the mortality was 62.5%. Blood clearance of myoglobin in 1 h was significantly greater with SHG (p = 0.02), particularly at 24 h (p = 0.17). Blood creatinine clearance did not differ significantly between the two membranes after 1 h, but SHG demonstrated slightly greater appearance at 24 h. There were no significant differences between the two membranes in the clearance of other solutes including HMGB-1.
Conclusions
This preliminary study compared the use of two polysulfone membranes in patients with sepsis requiring CRRT and showed that the polysulfone membrane SHG was capable of removing myoglobin with greater efficacy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Sekine, Kosuke 2 ; Abe, Takayuki 3 ; Suzaki, Shinichiro 4 ; Katsumi, Atsushi 4 ; Harada, Naoshige 4 ; Higashi, Hidenori 4 ; Kishihara, Yuki 4 ; Suzuki, Hidetaka 4 ; Takebayashi, Toru 5 1 Kameda Medical Center, Department of Intensive Care Unit, Kamogawa-shi, Japan (GRID:grid.414927.d) (ISNI:0000 0004 0378 2140); Japanese Red Cross Musashino Hospital, Intensive Care Unit, Department of Emergency and Critical Care Medicine, Tokyo, Japan (GRID:grid.410775.0) (ISNI:0000 0004 1762 2623); Keio University School of Medicine, Department of Preventive Medicine and Public Health, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)
2 Kameda Medical Center, Department of Medical Engineer, Chiba, Japan (GRID:grid.414927.d) (ISNI:0000 0004 0378 2140)
3 Keio University School of Medicine, Department of Preventive Medicine and Public Health, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959); Keio University Hospital, Biostatistics Unit at Clinical and Translational Research Center, Tokyo, Japan (GRID:grid.412096.8) (ISNI:0000 0001 0633 2119)
4 Japanese Red Cross Musashino Hospital, Intensive Care Unit, Department of Emergency and Critical Care Medicine, Tokyo, Japan (GRID:grid.410775.0) (ISNI:0000 0004 1762 2623)
5 Keio University School of Medicine, Department of Preventive Medicine and Public Health, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)




